Cambridge Investment Research Advisors
ARKG icon

Cambridge Investment Research Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.17M Sell
75,350
-11,284
-13% -$359K 0.01% 1337
2026
Q1 		$2.29M Sell
86,634
-4,612
-5% -$135K 0.01% 1496
2025
Q4 		$2.64M Buy
91,246
+8,186
+10% +$246K 0.01% 1313
2025
Q3 		$2.31M Buy
83,060
+6,375
+8% +$161K 0.01% 1394
2025
Q2 		$1.87M Sell
76,685
-17,432
-19% -$382K 0.01% 1483
2025
Q1 		$1.95M Buy
94,117
+839
+0.9% +$21.1K 0.01% 1372
2024
Q4 		$2.2M Sell
93,278
-16,318
-15% -$402K 0.01% 1298
2024
Q3 		$2.81M Sell
109,596
-2,214
-2% -$56.4K 0.01% 1118
2024
Q2 		$2.63M Sell
111,810
-3,574
-3% -$90.2K 0.01% 1105
2024
Q1 		$3.32M Sell
115,384
-8,501
-7% -$256K 0.01% 977
2023
Q4 		$4.07M Sell
123,885
-76,479
-38% -$2.08M 0.02% 806
2023
Q3 		$5.58M Sell
200,364
-9,782
-5% -$320K 0.03% 603
2023
Q2 		$7.16M Sell
210,146
-7,679
-4% -$241K 0.03% 492
2023
Q1 		$6.55M Buy
217,825
+12,532
+6% +$388K 0.03% 510
2022
Q4 		$5.79M Sell
205,293
-20,476
-9% -$650K 0.03% 546
2022
Q3 		$7.42M Buy
225,769
+11,969
+6% +$439K 0.04% 409
2022
Q2 		$6.73M Sell
213,800
-4,188
-2% -$146K 0.04% 460
2022
Q1 		$10M Sell
217,988
-44,596
-17% -$2.13M 0.05% 373
2021
Q4 		$16.1M Sell
262,584
-26,276
-9% -$1.82M 0.07% 257
2021
Q3 		$21.6M Sell
288,860
-27,851
-9% -$2.34M 0.11% 195
2021
Q2 		$29.3M Sell
316,711
-2,031
-0.6% -$173K 0.14% 146
2021
Q1 		$28.3M Buy
318,742
+63,718
+25% +$6.32M 0.15% 135
2020
Q4 		$23.8M Buy
255,024
+13,869
+6% +$1.1M 0.14% 147
2020
Q3 		$15.4M Buy
241,155
+114,168
+90% +$6.69M 0.1% 202
2020
Q2 		$6.62M Sell
126,987
-2,785
-2% -$119K 0.05% 349
2020
Q1 		$4.06M Buy
129,772
+1,505
+1% +$50.3K 0.04% 427
2019
Q4 		$4.3M Buy
128,267
+1,775
+1% +$56.4K 0.03% 517
2019
Q3 		$3.73M Buy
126,492
+7,687
+6% +$250K 0.03% 530
2019
Q2 		$4.09M Buy
118,805
+32,961
+38% +$1.06M 0.04% 473
2019
Q1 		$2.82M Buy
85,844
+11,330
+15% +$335K 0.03% 582
2018
Q4 		$1.79M Sell
74,514
-630
-0.8% -$17.8K 0.02% 677
2018
Q3 		$2.51M Buy
75,144
+21,583
+40% +$683K 0.02% 597
2018
Q2 		$1.56M Buy
53,561
+45,344
+552% +$1.26M 0.02% 753
2018
Q1 		$212K Buy
+8,217
New +$223K ﹤0.01% 1926

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Cambridge Investment Research Advisors's ARKG Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its ARK Genomic Revolution ETF (ARKG) stake by 13% in Q2 2026, selling an estimated $359K and leaving 75,350 shares worth $3.17M. The position accounts for 0.01% of the portfolio, ranked #1337.

Cambridge Investment Research Advisors first reported a position in ARKG in Q1 2018 and has held it in 34 quarters since. The position peaked at $29.3M in Q2 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Cambridge Investment Research Advisors held 75,350 shares of ARK Genomic Revolution ETF worth $3.17M as of Q2 2026.
  • Cambridge Investment Research Advisors sold 11,284 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $359K.
  • ARK Genomic Revolution ETF made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1337 holding.
  • Cambridge Investment Research Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2018 and has held it in 34 quarters since.
  • Cambridge Investment Research Advisors's ARK Genomic Revolution ETF position peaked at $29.3M in Q2 2021.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.